Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jviromet.2020.114009 http://scihub22266oqcxt.onion/10.1016/j.jviromet.2020.114009 33152411!7605757!33152411     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Virol+Methods 2021 ; 287 (ä): 114009 Nephropedia Template TP {{tp|p=33152411|t=2021. A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19 |pdf=|usr=}}{{33152411}} gab.com Text A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19 JO: J Virol Methods http://www.kidney.de/pget.php?&tw=1&pmid=33152411 #FOAvip BACKGROUND: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection. OBJECTIVE: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection. RESULTS: Clinical agreement studies were performed in 107 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 46.15 % (95 % CI: 19.22 % approximately 74.87 %), 61.54 % (95 % CI: 31.58 % approximately 86.14 %), and 97.53 % (95 % CI: 91.36 % approximately 99.70 %) for samples collected on 0-7 days, 8-14 days, and >/=15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23 % (95 % CI: 95.53 % approximately 99.52 %). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. CONCLUSION: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up anti-SARS-CoV-2 IgG testing. Twit Text FOAVip A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19 ????J Virol Methods http://www.kidney.de/pget.php?&tw=1&pmid=33152411 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33152411 #FOAvip English Wikipedia <ref>{{Cite pmid|33152411}}</ref> A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19 #MMPMID33152411 Du J; Chu E; Zhang D; Lu CM; Zhang A; Sha MY J Virol Methods 2021[Jan]; 287 (ä): 114009 PMID33152411show ga BACKGROUND: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection. OBJECTIVE: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection. RESULTS: Clinical agreement studies were performed in 107 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 46.15 % (95 % CI: 19.22 % approximately 74.87 %), 61.54 % (95 % CI: 31.58 % approximately 86.14 %), and 97.53 % (95 % CI: 91.36 % approximately 99.70 %) for samples collected on 0-7 days, 8-14 days, and >/=15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23 % (95 % CI: 95.53 % approximately 99.52 %). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. CONCLUSION: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up anti-SARS-CoV-2 IgG testing. |Antibodies, Viral/blood[MESH] |COVID-19 Serological Testing/*methods[MESH] |COVID-19/blood/*diagnosis[MESH] |High-Throughput Screening Assays[MESH] |Humans[MESH] |Immunoassay[MESH] |Immunoglobulin G/*blood[MESH] |Reproducibility of Results[MESH] |SARS-CoV-2/*immunology/isolation & purification[MESH]A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing